Skip to main content
Top

Current Hypertension Reports

Issue 2/2014

Content (5 Articles)

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Chronotherapeutics of Conventional Blood Pressure-Lowering Medications: Simple, Low-Cost Means of Improving Management and Treatment Outcomes of Hypertensive-Related Disorders

Ramón C. Hermida, Diana E. Ayala, Michael H. Smolensky, José R. Fernández, Artemio Mojón, Juan J. Crespo, María T. Ríos, Ana Moyá, Francesco Portaluppi

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles

Mohammed I Danjuma, Ipshita Mukherjee, Janine Makaronidis, Serge Osula

Hypertension and Metabolic Syndrome (J Sowers and A Whaley-Connell, Section Editors)

Innate Immunity in Hypertension

Muhammad Oneeb Rehman Mian, Pierre Paradis, Ernesto L. Schiffrin

Mediators, Mechanisms, and Pathways in Tissue Injury (T Fujita, Section Editor)

Corin in Natriuretic Peptide Processing and Hypertension

Yiqing Zhou, Qingyu Wu

Open Access Mediators, Mechanisms, and Pathways in Tissue Injury (T Fujita, Section Editor)

AT2 Receptor and Tissue Injury: Therapeutic Implications

Pawel Namsolleck, Chiara Recarti, Sébastien Foulquier, Ulrike Muscha Steckelings, Thomas Unger

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine